PARP1 and ovarian carcinoma: This latter mechanism of action may also explain why immune checkpoint inhibitors (e.g. against the PD-1/PD-L1 axis), which alone show no effect in ovarian cancer, act synergistically in combination with PARP inhibitors [3].